Has Medical Properties Trust’s 43% Rally Priced In Asset Sale Recovery?

• Wondering if Medical Properties Trust is a bargain right now? You're not the only one looking for value in this REIT, especially after some big recent moves.
• The stock has surged 43.5% year-to-date and is up 18.7% in the last month. However, these gains follow a tough couple of years, with the 5-year return still sitting at -57.8%.
• Recently, Medical Properties Trust has been in the headlines for its asset sales and strategic moves to strengthen the balance sheet, such as offloading facilities and partnering on recapitalizations. These developments have sparked renewed investor interest and may be reshaping the market's risk-reward view of the company.
• When we crunch the numbers, Medical Properties Trust has a valuation score of 5 out of 6, indicating it is undervalued by most of the checks that matter. Let's break down which valuation methods are flagging this opportunity, and why there may be an even smarter way to size up MPW as we wrap up the article.

Medical Properties Trust delivered 40.8% returns over the last year. See how this stacks up to the rest of the Health Care REITs industry.

Approach 1: Medical Properties Trust Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow (DCF) approach calculates what Medical Properties Trust is worth by estimating the future cash the business will generate and then discounting those cash flows back to their present value. In this case, the model uses adjusted funds from operations as a basis for projecting cash flows.

Currently, Medical Properties Trust is posting negative free cash flow, with the latest twelve months at -$1.4 billion. However, analysts project a significant turnaround. Over the next decade, free cash flow is expected to recover, reaching $301 million by 2026 and potentially growing to $517 million by 2035, as Simply Wall St extrapolates beyond available analyst estimates. These figures illustrate an anticipated stabilization and gradual growth in the company’s financial health over time.

Based on these forecasts, the DCF model estimates Medical Properties Trust’s intrinsic value at $7.31 per share. Considering the current market price, this suggests the stock is trading at a 21.1% discount to its fair value, implying that the market has not fully priced in the company’s recovery and future outlook.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Medical Properties Trust is undervalued by 21.1%. Track this in your watchlist or portfolio, or discover 928 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Medical Properties Trust.

Approach 2: Medical Properties Trust Price vs Sales

The Price-to-Sales (P/S) ratio is often preferred for valuing companies that might not have positive earnings but do generate substantial revenue, making it highly relevant for Medical Properties Trust, especially in periods of negative free cash flow. It helps investors understand how the market is valuing each dollar of the company’s sales, irrespective of temporary profitability pressures.

Growth expectations and perceived risks can both drive what investors consider a “normal” or “fair” P/S ratio. Companies with brighter growth prospects or lower risk generally command higher ratios, while those facing uncertainty or industry-specific challenges tend to trade at lower multiples.

Currently, Medical Properties Trust trades at a P/S ratio of 3.4x. This is well below the Health Care REITs industry average of 6.6x and the peer average of 7.9x. Simply Wall St’s proprietary Fair Ratio for Medical Properties Trust stands at 5.8x, which is crafted by considering not just the company’s industry but also its growth trends, balance sheet risks, profit margins, and market cap, providing a much more tailored view than a basic peer or sector comparison.

By comparing the Fair Ratio of 5.8x with Medical Properties Trust’s current P/S of 3.4x, the analysis points to a stock that is undervalued on this important metric. This substantial discount suggests the company may be trading below what its fundamental outlook would justify.

Result: UNDERVALUED

PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1439 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Medical Properties Trust Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is a simple, accessible way for investors to tell the story behind the numbers, combining their view on a company's future revenue, earnings, margins, and fair value into a clear, actionable investment thesis.

Narratives connect a company’s real-world story to its financial forecast and then directly to an estimated fair value, serving as a bridge between what is happening in the business and what the numbers suggest. On Simply Wall St’s platform, within the Community page, millions of investors use Narratives to articulate their views, track them over time, and compare their assumptions with others in real time.

This tool empowers investors to decide when to buy or sell by directly weighing Fair Value estimates against the current market Price, helping users act on their convictions with greater confidence. Narratives are updated dynamically every time new company news or quarterly results are released, ensuring that your perspective and valuations stay current with market developments.

For example, with Medical Properties Trust, some investors are bullish, projecting robust hospital demand and fair values as high as $6.00 per share, while more cautious investors emphasize ongoing risks and price targets near $4.00. This shows how Narratives can capture different perspectives and help everyone invest on their own terms.

Do you think there's more to the story for Medical Properties Trust? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com